Get complete Patent Opposition Report for Akebia Therapeutics

Comprehensive Analysis, Strategic Insights & Expert Evaluation – Stay Ahead in Your Patent Challenge.

Download Your Report Now

Latest oppositions filed by Akebia Therapeutics

Explore patent oppositions filed by Akebia Therapeutics against competitors, revealing strategic technology disputes and market positioning. Monitor opposition details, timelines, and disputed innovations to understand competitive dynamics and IP enforcement strategy.

Patent NumberTitleApplicantOpposition Date
EP2324834Methods Of Increasing Endogenous Erythropoietin (Epo)FIBROGENFeb 10, 2020
EP2289531Medicaments For Increasing Endogenous Erythropoietine (Epo)FIBROGENApr 3, 2019
EP2298301Medicaments For Increasing Endogenous Erythropoietin (Epo)FIBROGENApr 3, 2019
EP2322153Use Of Hif Alpha Stabilizers For Enhancing ErythropoiesisFIBROGENJul 6, 2015

Explore Akebia Therapeutics's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Patent NumberGrant DateTitleTotal Oppositions
EP3007695Feb 7, 2024Compositions And Methods For Treating Anemia2
EP3357911May 11, 2022Prolyl Hydroxylase Inhibitors And Methods Of Use1
EP3277270Oct 27, 2021Compositions And Methods For Treating Anemia1